Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Johnson & Johnson (JNJ) - free report >>
Pfizer Inc. (PFE) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) - free report >>
Pfizer Inc. (PFE) - free report >>
Image: Bigstock
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
Pfizer, Inc. (PFE - Free Report) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.’s (ABBV - Free Report) Humira.
Xeljanz (5 mg twice daily), a JAK inhibitor, is presently approved as a second-line treatment for the treatment of moderate-to-severely active RA in patients who have had an inadequate response to or cannot tolerate methotrexate. In Feb 2016, the FDA approved a once-daily extended-release (XR) formulation of Xeljanz (11 mg) tablets.
The phase IIIb/IV ORAL Strategy study (n=1,152) compared Xeljanz (5 mg twice daily) as a monotherapy or in combination with methotrexate (MTX) versus Humira plus MTX. The study demonstrated non-inferiority of Xeljanz plus MTX versus Humira plus MTX, thereby meeting the primary endpoint. However, Xeljanz monotherapy did not demonstrate non-inferiority versus Humira plus MTX, thereby failing to meet the primary endpoint.
Pfizer’s shares are up 3.5% so far this year, in line with the Zacks classified Large-Cap Pharma industry.
Overall safety results from these studies were found to be consistent with those observed in the broader rheumatology development program for Xeljanz.
Xeljanz sales in 2016 were $927 million, up 77% from the prior-year quarter. Xeljanz (5 mg, twice daily) is under regulatory review in the EU.
Xeljanz is being studied for the treatment of active psoriatic arthritis (PsA) and ulcerative colitis. Label and geographical expansion will boost the drug’s commercial potential significantly.
Blockbuster drugs currently approved to treat RA include Johnson & Johnson’s (JNJ - Free Report) Remicade and Amgen, Inc.’s (AMGN - Free Report) Enbrel that Pfizer markets outside the U.S. and Canada.
Pfizer carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>